Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

BriaCell Therapeutics Corp. (BCTXF) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/18/2022 6-K Quarterly results
07/05/2022 6-K Quarterly results
06/29/2022 6-K Quarterly results
06/24/2022 6-K Quarterly results
06/13/2022 6-K Quarterly results
05/18/2022 6-K Quarterly results
04/13/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File Number: 001-40101 BRIACELL THERAPEUTICS CORP. Suite 300 – 235 15 th Street West Vancouver, BC V7T 2X1 Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☐ Form 40-F ☒ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Exhibit Number Description 99.1 Press Release dated April 13...",
"Director of Public Relations"
04/12/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File Number: 001-40101 BRIACELL THERAPEUTICS CORP. Suite 300 – 235 15 th Street West Vancouver, BC V7T 2X1 Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☐ Form 40-F ☒ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Exhibit Number Description 99.1 Press Release dated April 12...",
"Director of Public Relations"
04/07/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File Number: 001-40101 BRIACELL THERAPEUTICS CORP. Suite 300 – 235 15 th Street West Vancouver, BC V7T 2X1 Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☐ Form 40-F ☒ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Exhibit Number Description 99.1 Press Release dated April 7,...",
"Jules Abraham Director of Public Relations CORE IR 917-885-7378"
03/15/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Condensed Interim Consolidated Financial Statements",
"Management’ s Discussion and Analysis For the Three and Six Month Period Ended January 31, 2022 BriaCell Therapeutics Corp Management’ s Discussion and Analysis For the three and six month period ended January 31, 2022 1. Management’ s Discussion and Analysis The following discussion and analysis are management’ s assessment of the results and financial condition of BriaCell Therapeutics Corp. . The following information should be read in conjunction with the audited financial statements for the year ended July 31, 2021 and the unaudited condensed interim financial statements for the three and six months ended January 31, 2022 and the notes to those financial statements, all of which are available on BriaCell’ s issuer profile on SEDAR at www.sedar.com and on the Company’ s website at www...."
02/28/2022 6-K Quarterly results
02/23/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2022 Commission File Number: 001-40101 BRIACELL THERAPEUTICS CORP. Suite 300 – 235 15 th Street West Vancouver, BC V7T 2X1 Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☐ Form 40-F ☒ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Exhibit Number Description 99.1 Press Release dated Febru...",
"Jules Abraham Director of Public Relations CORE IR 917-885-7378"
02/16/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2022 Commission File Number: 001-40101 BRIACELL THERAPEUTICS CORP. Suite 300 – 235 15 th Street West Vancouver, BC V7T 2X1 Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☐ Form 40-F ☒ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Exhibit Number Description 99.1 Press Release dated Febru...",
"Jules Abraham Director of Public Relations CORE IR 917-885-7378"
02/10/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2022 Commission File Number: 001-40101 BRIACELL THERAPEUTICS CORP. Suite 300 – 235 15 th Street West Vancouver, BC V7T 2X1 Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☐ Form 40-F ☒ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Exhibit Number Description 99.1 Press Release dated Febru...",
"Director of Public Relations"
01/20/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2022 Commission File Number: 001-40101 BRIACELL THERAPEUTICS CORP. Suite 300 – 235 15 th Street West Vancouver, BC V7T 2X1 Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☐ Form 40-F ☒ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Exhibit Number Description 99.1 Press Release dated Januar...",
"Director of Public Relations",
"Report of Voting Results for Matters Voted Upon at Annual General and Special Meeting of Shareholders of BriaCell Therapeutics Corp"
12/30/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-40101 BRIACELL THERAPEUTICS CORP. Suite 300 – 235 15 th Street West Vancouver, BC V7T 2X1 Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☐ Form 40-F ☒ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Exhibit Number Description 99.1 Press Release dated Decem...",
"Jules Abraham Director of Public Relations CORE IR 917-885-7378"
12/16/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-40101 BRIACELL THERAPEUTICS CORP. Suite 300 – 235 15 th Street West Vancouver, BC V7T 2X1 Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☐ Form 40-F ☒ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Exhibit Number Description 99.1 Press Release dated Decem...",
"Director of Public Relations"
12/15/2021 6-K Quarterly results
12/09/2021 6-K Quarterly results
11/12/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-40101 BRIACELL THERAPEUTICS CORP. Suite 300 – 235 15 th Street West Vancouver, BC V7T 2X1 Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☐ Form 40-F ☒ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Exhibit Number Description 99.1 Press Release dated Novem...",
"Director of Public Relations",
"Notice of Meeting"
11/05/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-40101 BRIACELL THERAPEUTICS CORP. Suite 300 – 235 15 th Street West Vancouver, BC V7T 2X1 Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☐ Form 40-F ☒ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Exhibit Number Description 99.1 Press Release dated Novem...",
"Director of Public Relations"
11/02/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-40101 BRIACELL THERAPEUTICS CORP. Suite 300 – 235 15 th Street West Vancouver, BC V7T 2X1 Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☐ Form 40-F ☒ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Exhibit Number Description 99.1 Press Release dated...",
"Jules Abraham Director of Public Relations CORE IR 917-885-7378"
10/29/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2021 Commission File Number: 001-40101 BRIACELL THERAPEUTICS CORP. Suite 300 – 235 15 th Street West Vancouver, BC V7T 2X1 Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☐ Form 40-F ☒ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Exhibit Number Description 99.1 BriaCell Therapeutics Corp...",
"BriaCell Therapeutics Corp. Consolidated Financial Statements for the years ended July 31, 2021 and 2020",
"BriaCell Therapeutics Corp. Management’ s Discussion and Analysis for the year ended July 31, 2021",
"Annual Information Form for BriaCell Therapeutics Corp. for the year ended July 31, 2021"
10/05/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2021 Commission File Number: 001-40101 BRIACELL THERAPEUTICS CORP. Suite 300 – 235 15 th Street West Vancouver, BC V7T 2X1 Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ ] Form 40-F [X] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: [ ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: [ ] Exhibit Number Description 99.1 Press Release dated October 5, 2021 issued...",
"Jules Abraham Director of Public Relations CORE IR 917-885-7378"
09/22/2021 6-K Quarterly results
09/09/2021 6-K Quarterly results
09/01/2021 6-K Quarterly results
08/23/2021 6-K Quarterly results
08/19/2021 6-K Quarterly results
08/17/2021 6-K Quarterly results
08/12/2021 6-K Quarterly results
07/14/2021 6-K Quarterly results
07/12/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2021 Commission File Number: 001-40101 BRIACELL THERAPEUTICS CORP. Suite 300 – 235 15 th Street West Vancouver, BC V7T 2X1 Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [X] Form 40-F [ ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: [ ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: [ ] Exhibit Number Description 99.1 Press Release, dated July 12, 2021, issued by...",
"Director of Public Relations"
07/08/2021 6-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy